Close Menu
Bad Mortgage
    What's Hot

    KBRA Assigns Preliminary Ratings to BRAVO Residential Funding Trust 2026-NQM4 (BRAVO 2026-NQM4)

    Harbinger Of Bankruptcies To Come

    SBA Deputy Admin visits, shares deadlines for disaster assistance loans and how to apply

    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    Bad MortgageBad Mortgage
    • Home
    • Shop
    • Mortgage
    • Real Estate
    • Loans
    • Credit Loans
    • Foreclosure Help
    • Refinance Rates
    Bad Mortgage
    Home»Loans»SHINE Receives Conditional Commitment for $263 Million DOE Loan to Scale Domestic Medical Isotope Manufacturing Using Fusion Technology
    Loans

    SHINE Receives Conditional Commitment for $263 Million DOE Loan to Scale Domestic Medical Isotope Manufacturing Using Fusion Technology

    By No Comments3 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    SHINE Receives Conditional Commitment for $263 Million DOE Loan to Scale Domestic Medical Isotope Manufacturing Using Fusion Technology
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Chrysalis represents the first deployment of new nuclear technology at this scale in decades. The facility uses novel American-made fusion systems to produce Mo-99—a life-saving medical isotope used in over 40,000 procedures daily to diagnose heart disease, cancer, and other serious medical conditions. By establishing U.S. production capability, Chrysalis addresses a critical national security vulnerability while demonstrating American leadership in advanced nuclear systems.

    “Chrysalis proves that fusion doesn’t need to wait for future breakthroughs to create value for millions of people today,” said Greg Piefer, founder and CEO of SHINE. “This conditional commitment is a critical catalyst that accelerates our scale-up of the world’s largest medical isotope facility and ensures a secure, domestic source of critical medical isotopes. We are incredibly grateful to the Department of Energy’s rigorous due diligence process and look forward to working to meet the conditions to move forward on the loan.”

    The United States currently relies on imports from Europe, South Africa and Australia for its Mo-99 supply. These imports are produced in venerable but aging research reactors that are nearing or at capacity. Mo-99 decays at about 1 percent per hour, so the U.S. loses roughly one-third of its volume and value during cross-continental transportation. Chrysalis will shore up global supply chains as the only new multi-million dose per year infrastructure expected in the next decade, eliminating logistical vulnerabilities while providing secure, reliable domestic supply.

    SHINE’s process uses fusion and a liquid uranium target that is recycled. This reduces both waste volume and operating costs.

    This milestone is the culmination of more than 15 years of significant collaboration with U.S. National Laboratories and consistent support from the National Nuclear Security Administration (NNSA). This conditional commitment is instrumental in demonstrating the reliability and safety of SHINE’s fusion-based approach, which provides a modern, sustainable alternative to aging nuclear reactors. 

    Once fully operational, Chrysalis will be the largest medical isotope production facility in the world, demonstrating fusion technology at commercial scale. While primarily focused on Mo-99, the facility is designed to be a versatile source for other critical isotopes, including iodine-131, xenon-133 and many others.

    Chrysalis represents a significant investment in American advanced manufacturing and domestic supply chains. The project is a cornerstone of Janesville’s transition from its historical automotive roots to a high-tech nuclear future, supporting approximately 200 construction jobs and 150 permanent operations positions.

    While this conditional commitment from EDF indicates the Department’s intent to provide a loan to finance the project, DOE and the company must satisfy certain technical, legal, environmental, and financial conditions before the Department enters into definitive financing documents and funds the loan. 

    About SHINE

    Headquartered in Janesville, Wisconsin, SHINE is an industry leader in next-generation fusion, developing innovative fusion-based technology that combines safety, cost-efficiency and environmental responsibility.

    SHINE has successfully commercialized fusion across multiple applications, including neutron testing markets such as neutron radiography, radiation-effects testing and fusion material research. It has commercialized and is scaling its proprietary medical isotope production, processes, supplying high-quality radioisotopes essential for procedures including diagnosing heart disease and cancer as well as cancer therapy.

    Beyond these applications, SHINE is pioneering nuclear waste recycling to make nuclear energy more sustainable. Its long-term purpose is to change the way humans make energy by commercializing fusion energy. Unlike other fusion companies, SHINE takes a commercially driven path mirroring successful deep-tech industries. Through this visionary approach, SHINE is advancing technology, healthcare, and sustainable energy, making a lasting impact across multiple sectors.  Learn more at www.shinefusion.com

    SOURCE SHINE Technologies, LLC

    Commitment Conditional DOE Domestic Fusion Isotope loan manufacturing medical million receives scale SHINE Technology
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleEvergreen Home Loans Selects Dara by Sagent to Power Modern, End-to-end Mortgage Servicing
    Next Article DSCR Loans Explained: How Investors Compare DSCR Loan Rates and Requirements in Today's Market
    • Website

    Related Posts

    SBA Deputy Admin visits, shares deadlines for disaster assistance loans and how to apply

    DSCR Loans Explained: How Investors Compare DSCR Loan Rates and Requirements in Today's Market

    Paramount M&A Loan Cut to $49 Billion as Lending Group Swells

    Add A Comment
    Leave A Reply Cancel Reply

    Top Posts

    KBRA Assigns Preliminary Ratings to BRAVO Residential Funding Trust 2026-NQM4 (BRAVO 2026-NQM4)

    Harbinger Of Bankruptcies To Come

    SBA Deputy Admin visits, shares deadlines for disaster assistance loans and how to apply

    Subscribe to Updates

    Get the latest sports news from SportsSite about soccer, football and tennis.

    About Us

    Welcome to Bad Mortgage, your trusted resource for navigating the complex world of mortgages, home loans, and real estate—especially when facing financial challenges.
    We understand that not everyone has a perfect credit score or an ideal financial history. At Bad Mortgage, our mission is to provide clear, reliable, and practical information to help individuals make informed decisions about their home financing options, regardless of their financial situation.

    Facebook X (Twitter) Instagram Pinterest YouTube
    Top Insights

    KBRA Assigns Preliminary Ratings to BRAVO Residential Funding Trust 2026-NQM4 (BRAVO 2026-NQM4)

    Harbinger Of Bankruptcies To Come

    SBA Deputy Admin visits, shares deadlines for disaster assistance loans and how to apply

    Get Informed

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    © 2026 badmortgage.org. All rights reserved. Designed by DD.

    • About Us
    • Contact Us
    • Terms & Conditions
    • Privacy Policy
    • Disclaimer

    Type above and press Enter to search. Press Esc to cancel.